empagliflozin + ezetimibe + rosuvastatin

This is a fixed-dose combination of three small molecule drugs—empagliflozin, ezetimibe, and rosuvastatin—each with distinct mechanisms of action targeting cardiovascular and metabolic risk factors. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily for the management of type 2 diabetes mellitus by promoting urinary glucose excretion. Ezetimibe is a cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing dietary cholesterol absorption[6]. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that decreases hepatic cholesterol synthesis and increases LDL receptor expression to lower plasma LDL-cholesterol levels[3][6]. The combination would be expected to provide additive or synergistic benefits in patients requiring both glycemic control and intensive lipid lowering, such as those at high risk for cardiovascular disease.

Other names

rosuvastatin-Hyundai Pharm-type 2 diabetes mellitus-dyslipidemiasHODO-22251 + HODO-22252